ライフサイエンスコーパス: resectable

1 after PVE, of whom 3 patients (11%) were not resectable.

2 se; however, tumors may remain surgically un-resectable.

3 local/in-transit or nodal, asymptomatic, or resectable.

4 atients initially not judged to be optimally resectable.

5 hat 13% to 16% of patients could be rendered resectable.

6 tly identified 88% and 92%, respectively, as resectable.

7 icroscopic histologic margins was considered resectable.

8 followed by laparotomy if the tumor appeared resectable.

9 xcision, whereas malignant tumors are seldom resectable.

10 Of the 27 CT-detected cancers, 26 were resectable.

11 Thirty-nine tumors never became resectable.

12 ith melanoma diagnosed as having potentially resectable abdominal metastases before (1969-2003) and a

13 le-center, single-arm study of patients with resectable adenocarcinoma of the pancreas who were treat

14 nosed with stage II to III locally advanced, resectable adenocarcinoma of the rectum with a distal tu

15 adiotherapy on the survival of patients with resectable adenocarcinoma of the stomach or gastroesopha

16 We randomly assigned patients with resectable adenocarcinoma of the stomach, esophagogastri

17 overed in this review are as follows: who is resectable; adjunctive surgical techniques that can impr

18 If the disease becomes resectable, adjuvant treatment should follow surgery.

19 However, in some cases, tumors seem resectable after chemotherapy through aggressive use of

20 rrent standards of therapy for patients with resectable and advanced pancreatic cancer and review new

21 -Biliary Association Consensus Conference on Resectable and Borderline Resectable Disease.

22 The primary goal of care for patients with resectable and borderline-resectable tumors is cure, fac

23 stem, blood samples from patients with local resectable and metastatic pancreatic ductal adenocarcino

24 proved the accuracy of the identification of resectable and nonresectable disease over that of CT (80

25 as well as in the diagnosis and treatment of resectable and nonresectable PNETs.

26 s with metastatic disease, and management of resectable and potentially resectable metastases-and how

27 n (SLT) strategy was conceived for initially resectable and transplantable (R&T) hepatocellular carci

28 organ preservation in patients with advanced resectable and unresectable (nasopharyngeal) tumors.

29 f nelfinavir chemoradiotherapy in borderline resectable and unresectable pancreatic cancer.

30 ls that impact mesothelioma treatment in the resectable and unresectable settings, discuss the impact

31 he setting of locally advanced disease--both resectable and unresectable.

32 y (n = 80) or whose lesions were potentially resectable and who refused surgery (n = 19) were include

33 astases that are unresectable rendering them resectable, and decrease postoperative recurrence rates

34 presenting with distant metastases, are not resectable, and have a 5-year survival rate of close to

35 categories: nonrecurrent, recurrent but not resectable, and recurrent but resectable with curative i

36 y 31, 2010, and stratified to 1 of 3 groups: resectable (arm A), limited metastatic (arm B), or exten

37 Patients whose tumors remained resectable at restaging proceeded to operation and subse

38 who preoperatively appeared to be marginally resectable but had a tumor-free left lateral lobe.

39 py with respect to surgery for patients with resectable but high-risk urothelial cancer.

40 spected pancreatic cancer deemed potentially resectable by 1 or both tests were considered for surger

41 proven non-small cell lung cancer considered resectable by standard imaging, including routine preope

42 copy prior to laparotomy in patients with CT-resectable cancer appears to be cost-effective in pancre

43 In resectable cancer it was 27%.

44 ering adjuvant chemotherapy in patients with resectable cancer of the esophagus treated with preopera

45 y improve the outlook for some patients with resectable cancer.

46 d the management in patients with surgically resectable cancer.

47 The greatest need was for patients with resectable cancer.

48 eased in comparison to patients with clearly resectable cancers at the time of presentation.

49 age; and 38.2% (3,644/9559) with potentially resectable cancers were classified as "not offered surge

50 NLR, PLR, LMR and GPS/mGPS in patients with resectable cancers.

51 ancer, representing approximately 10% of all resectable cases.

52 To establish a mouse model of resectable cholangiocarcinoma including the most frequen

53 e, OS is comparable with liver resection for resectable CLMs and survival after repeat liver transpla

54 predicted the status of the nodal basin for resectable colon cancer and, therefore, could be extensi

55 For patients with resectable colon cancer, improved identification of LN d

56 rial of neoadjuvant chemotherapy in advanced resectable colon cancer, improvement of the plane of dis

57 conventional histopathology in patients with resectable colon cancer.

58 isease and improves staging in patients with resectable colon cancer.

59 rately predicted LN status for patients with resectable colon cancer.

60 unlikely to improve risk stratification for resectable colon cancer.

61 for 449 consecutive patients with clinically resectable colon cancer.

62 nation of efficacious adjuvant therapies for resectable colorectal cancer has not been comprehensivel

63 Ninety patients with resectable colorectal cancer metastatic to the liver und

64 arch 2001 and August 2006, 152 patients with resectable colorectal cancer were enrolled in the trial.

65 exon 2 wild-type resectable or suboptimally resectable colorectal liver metastases were randomised i

66 ab to standard chemotherapy in patients with resectable colorectal liver metastasis.

67 n 2001 and 2007, 253 evaluable patients with resectable CRC were enrolled.

68 c resection can improve OS for patients with resectable CRHM.

69 Patients with surgically resectable disease (< or = cT4aN0M0) received a total of

70 sociated with poor survival in patients with resectable disease (HR: 1.37; 95% CI: 1.15-1.63) but not

71 y to detect CTCs in PDAC patients with local resectable disease (mean = 11 CTCs per mL).

72 ith pancreatic and periampullary cancer with resectable disease based on CT scanning.

73 nocarcinoma who otherwise are viewed to have resectable disease but have preoperative findings of ext

74 l for patients with resectable or borderline-resectable disease may be warranted.

75 ividuals undergoing treatment for surgically resectable disease may experience recurrence near the re

76 in a small subset of patients with localized resectable disease proven to be platinum sensitive.

77 patients with pancreatic cancer do not have resectable disease, and the recent thoughts on palliatio

78 Around 15-20% of patients have resectable disease, but only around 20% of these survive

79 cytoreductive surgery, and with potentially resectable disease, may receive either neoadjuvant chemo

80 However, only 20% of patients present with resectable disease.

81 nsus Conference on Resectable and Borderline Resectable Disease.

82 as 43% (95% CI, 28% to 58%) in patients with resectable disease.

83 patients were enrolled, and of these 43 had resectable disease.

84 r and increasing cure rates among those with resectable disease.

85 ce between surgery and CRT for patients with resectable disease.

86 patients with compensated cirrhosis and non-resectable early stage hepatocellular carcinoma.

87 dependent prognostic factor in patients with resectable EC.

88 ly from 100 patients who were judged to have resectable EC.

89 apy is established in the management of most resectable esophageal and esophagogastric junction adeno

90 Y BACKGROUND DATA: The optimal treatment for resectable esophageal cancer is unknown.

91 a primary treatment option for patients with resectable esophageal cancer.

92 effective strategy in improving survival of resectable esophageal cancer.

93 surgery alone for patients with potentially resectable esophageal carcinoma did not demonstrate a st

94 pilot study of 43 patients with potentially resectable esophageal carcinoma treated with an intensiv

95 rapy as a standard of care for patients with resectable esophagogastric cancer.

96 ll beta-cells or only in beta-cells within a resectable focal lesion.

97 st at a time when the cancer was potentially resectable for cure.

98 Thirty-seven patients (93%) proved resectable for cure.

99 7 to May 2001, 100 patients with potentially resectable gallbladder cancer (n = 44) and hilar cholang

100 For surgically resectable gastric cancer, removal of 15 or more lymph n

101 motherapy to treat patients with potentially resectable gastric cancer.

102 y is predictive of survival in patients with resectable gastric cancer.

103 rate, safety, and survival in patients with resectable gastric carcinoma.

104 preoperatively in patients with potentially resectable gastric carcinoma.

105 erative therapy in patients with potentially resectable gastric carcinoma.

106 capecitabine chemotherapy for patients with resectable gastric, oesophagogastric junction, or lower

107 peri-operative chemotherapy in patients with resectable gastric, oesophagogastric junction, or lower

108 estimate disease-specific survival (DSS) for resectable gastroesophageal (GE) junction and gastric ad

109 ong MMRD, MSI, and survival in patients with resectable gastroesophageal cancer randomized to surgery

110 Patients with resectable gastrointestinal stromal tumors (GISTs) might

111 In patients with resectable GE junction and gastric adenocarcinoma, pretr

112 to render initially unresectable metastases resectable has increased the percentage of patients elig

113 f resection in disease that is not optimally resectable has not been as well studied.

114 nge, 53-79 years; mean age, 66.2 years) with resectable HCC (diameter, 2.9-6.0 cm; mean, 4.2 cm) unde

115 Children with initially resectable HCC have a good prognosis and may benefit fro

116 ed trials on the role of adjuvant therapy in resectable HCC.

117 Among patients with potentially resectable hepatic metastases of colorectal adenocarcino

118 tumor in 25% of patients considered to have resectable hepatic metastasis by conventional staging.

119 by Radiotherapy Versus Radiochemotherapy for Resectable High Risk Squamous Cell Carcinoma of the Head

120 At diagnosis, patients age </= 40 years with resectable high-grade osteosarcoma were registered.

121 ild on the apparent benefit of IFNalpha2b in resectable high-risk American Joint Committee on Cancer

122 is the only established adjuvant therapy of resectable high-risk melanoma.

123 Consenting patients with newly diagnosed, resectable, high-grade osteosarcoma aged 40 years or you

124 tients with locally advanced but potentially resectable hilar cholangiocarcinoma, the yield of laparo

125 have developed a murine model of single, R0-resectable ICC with favorable characteristics for the st

126 HCC was detected earlier and was more often resectable in patients who had twice yearly screening wi

127 nts whose tumors were reevaluated and deemed resectable in the last week of radiotherapy were randoml

128 t approach that includes surgical removal if resectable, in combination with multiagent chemotherapy

129 Twenty-seven patients with radiographically resectable intermediate- or high-grade soft tissue sarco

130 en June 2009 and March 2011, patients with a resectable intrathoracic esophageal carcinoma, including

131 of patients with locally advanced/borderline resectable (LA/BR) pancreatic ductal adenocarcinoma (PDA

132 distinction between patients presenting with resectable lesions (neoadjuvant) versus patients present

133 Eighty-eight patients had resectable lesions according to CT angiographic criteria

134 g unresectable liver metastases, but not for resectable lesions, for which adjuvant chemotherapy is p

135 For resectable lesions, studies on neoadjuvant chemotherapy

136 ery alone for patients with initially 1 to 4 resectable liver metastases from colorectal cancer (CRC)

137 after 1 cycle of treatment in patients with resectable liver metastases from colorectal cancer, with

138 Some suggest that resectable liver metastases, in the absence of high-risk

139 the survival for a patient with a solitary, resectable liver metastasis is better than that for a pa

140 and enables curative resection of marginally resectable liver tumors or metastases in patients that m

141 Careful patient selection of those with resectable liver-only metastatic disease is crucial to t

142 Patients with radiographically resectable localized adenocarcinoma of the pancreatic he

143 ntation protocols for curative intent in non-resectable localized disease have been described.

144 d radical radiation therapy in patients with resectable, locally advanced head and neck cancer.

145 All newly diagnosed, resectable lung cancer patients receiving treatment at t

146 cer of any stage or a proven but potentially resectable lung cancer were prospectively selected after

147 uperior oncologic outcomes for patients with resectable lung cancer.

148 Improvements in outcomes for patients with resectable lung cancers have plateaued.

149 for survival in future neoadjuvant trials of resectable lung cancers.

150 ery high-risk melanoma (including those with resectable M1 disease).

151 ant differences in survival observed between resectable mesenteric lymph nodes versus unresectable ma

152 at have been made in surgical techniques for resectable metastases and the impact of modern chemother

153 h colorectal cancer treated by surgery, with resectable metastases based on CT scans of the chest, ab

154 Patients with one to three potentially resectable metastases were randomized preoperatively to

155 and management of resectable and potentially resectable metastases-and how these strategies can be ap

156 with liver metastases are considered to have resectable metastases.

157 In resectable MRD, PNB-guided surgery prevented local recur

158 median age, 64 years; 27 men, 17 women) with resectable (n = 12), unresectable (n = 29), and metastat

159 atively, and 53 (66%) treated surgically had resectable (n = 25) or unresectable (n = 28) cancer.

160 screening led to the detection of surgically resectable neoplastic disease in several family members.

161 erapy remains the most advisable therapy for resectable neuroendocrine tumors of the pancreas, there

162 FFS at 3 years for patients with resectable node-positive or unresectable (group III) emb

163 ode involvement in patients with potentially resectable non-small cell lung cancer (NSCLC)?

164 and 2001 from 24 individuals with surgically resectable non-small cell lung cancer, i.e., adenocarcin

165 PET) scan after neoadjuvant chemotherapy for resectable non-small-cell lung cancer (NSCLC) is prognos

166 vivo) response in patients with early-stage resectable non-small-cell lung cancer (NSCLC).

167 ressed in approximately 35% of patients with resectable non-small-cell lung cancer (NSCLC).

168 f age or older who were given a diagnosis of resectable non-small-cell lung cancer (stage I or II) be

169 erm results of combined-modality therapy for resectable non-small-cell lung cancer is hampered by ins

170 Clinical trials of resectable non-small-cell lung cancers with overall surv

171 Patients with early-stage, resectable, non-small-cell lung cancer (NSCLC) are at ri

172 We investigated the prevalence of OMs in resectable NSCLC and their relationship with survival.

173 of preoperative (induction) chemotherapy in resectable NSCLC demonstrated feasibility and encouragin

174 Potentially resectable NSCLC lesions missed at chest radiography wer

175 Among patients with resectable NSCLC treated with neoadjuvant chemotherapy,

176 d a prospective data set of 77 patients with resectable NSCLC were studied.

177 in an independent cohort of 96 patients with resectable NSCLC.

178 be useful as adjuvant therapy for surgically resectable NSCLC.

179 nel lymph node (SN) mapping in patients with resectable NSCLC.

180 single option for patients with potentially resectable NSCLC.

181 aminations were performed in 35 patients (36 resectable NSCLCs) between 2009 and 2014.

182 Patients with surgically resectable oesophageal adenocarcinoma classified as stag

183 years and older with histologically proven, resectable oesophagogastric adenocarcinoma from 87 UK ho

184 gery is a standard of care for patients with resectable oesophagogastric adenocarcinoma.

185 a larger, randomized trial for patients with resectable or borderline-resectable disease may be warra

186 ients aged 18 years or older with borderline resectable or locally advanced biopsy-proven pancreatic

187 spective, phase 2 trial of 252 patients with resectable or metastatic gastric or gastroesophageal jun

188 in patients with localized disease, whether resectable or not.

189 Patients with KRAS exon 2 wild-type resectable or suboptimally resectable colorectal liver m

190 4 weeks until their tumors became surgically resectable or they showed signs of disease progression.

191 omitantly with radiotherapy to patients with resectable or unresectable advanced disease, chemotherap

192 ng resectability to a definitive answer (ie, resectable or unresectable) when the reports were struct

193 with newly diagnosed stage III (incompletely resectable) or stage IV epithelial ovarian cancer who ha

194 The 9 patients with nonmetastatic, resectable, or borderline-resectable PBCs had a mean of

195 rcalated surgery is the standard of care for resectable OS in those younger than 40 years.

196 34 patients had PD with PV/SMV resection for resectable PA on preoperative staging.

197 The role for neoadjuvant systemic therapy in resectable pancreas adenocarcinoma remains undefined.

198 herapy is worthy of further investigation in resectable pancreas adenocarcinoma.

199 red as preoperative therapy in patients with resectable pancreas adenocarcinoma.

200 chemoradiation was used in 154 patients with resectable pancreatic adenocarcinoma (142 patients, 92%)

201 Thirty-nine patients suspected of having resectable pancreatic adenocarcinoma underwent triple-ph

202 Patients with localized, potentially resectable pancreatic adenocarcinoma were treated with 3

203 so received adjuvant therapy-for early-stage resectable pancreatic adenocarcinoma.

204 patient selection tool, in the management of resectable pancreatic adenocarcinoma.

205 t improve prognostic accuracy in LN-positive resectable pancreatic adenocarcinoma.

206 workup of preoperative SCPN in patients with resectable pancreatic adenocarcinoma.

207 enever possible in patients with potentially resectable pancreatic and peripancreatic lesions.

208 cal resection for patients with early-stage, resectable pancreatic cancer are associated with socioec

209 ly, it appears that a third of patients with resectable pancreatic cancer do not receive an operation

210 -1, the largest randomized adjuvant study of resectable pancreatic cancer ever performed, set out to

211 -institutional neoadjuvant phase II study in resectable pancreatic cancer is planned.

212 his has led to the definition of "borderline resectable pancreatic cancer"--a new clinical category t

213 ort the preoperative treatment of borderline resectable pancreatic cancer, no prospective, quality-co

214 ss discriminatory power for the detection of resectable pancreatic cancer, with high specificity and

215 bility and overall survival of patients with resectable pancreatic cancer.

216 biomarkers for the noninvasive detection of resectable pancreatic cancer.

217 of gemcitabine-based preoperative therapy in resectable pancreatic cancer.

218 sociated diabetes might lead to diagnosis of resectable pancreatic cancer.

219 burden associated with treatment options for resectable pancreatic cancer.

220 atients was different than that reported for resectable pancreatic cancers, implying a biologic basis

221 tandard of care in the adjuvant treatment of resectable pancreatic ductal adenocarcinoma (PDAC).

222 Of the 25 resectable pancreatic tumors in patients recommended for

223 Transgenic mice with resectable pancreatic tumors might be promising tools to

224 One resectable patient was considered a complete pathologic

225 cantly higher in nonresectable (46%) than in resectable patients (11.7%), P < 0.001.

226 yzing all patients (P = 0.002) and analyzing resectable patients (P < 0.001).

227 Cs, 31% of the nonresectable and 9.1% of the resectable patients (P = 0.001).

228 urvival estimates differed significantly for resectable patients exposed to low doses (50 to 150 mg/m

229 Resectable patients underwent surgery 4 to 6 weeks after

230 Forty-four resectable patients with MPM underwent pleurectomy, foll

231 val rates were 73% for all patients, 94% for resectable patients, 76% for borderline-resectable patie

232 for resectable patients, 76% for borderline-resectable patients, and 47% for unresectable patients.

233 d resectable, three (33%) of nine borderline-resectable patients, and one (7%) of 14 unresectable pat

234 but not associated with clinical outcome in resectable patients.

235 ach test in detecting group 3 (recurrent but resectable) patients was calculated.

236 ith nonmetastatic, resectable, or borderline-resectable PBCs had a mean of 83.2 CTCs/7.5 mL portal ve

237 is recommended for patients with borderline resectable PC and, at some centers, neoadjuvant therapy

238 t therapy has been extended to patients with resectable PC as well.

239 icant increase in survival for patients with resectable PDA.

240 improve survival in patients with primarily resectable PDAC after R0 resection.

241 In a transgenic mouse model of resectable PDAC, we investigated the coordinated activat

242 tive gemcitabine-based chemoradiotherapy for resectable PDAC.

243 were similar to the 65%, 14%, 16% and 5% for resectable periampullary cancers found in the primary su

244 t study randomizes patients with potentially resectable PHC and biliary obstruction between preoperat

245 All patients with potentially resectable primary gallbladder cancer and patients with

246 Thirty-five patients with radiographically resectable primary or recurrent intermediate- or high-gr

247 ts were stratified at enrollment: stratum A, resectable primary tumor without metastases; stratum B,

248 ember 1994 and March 1997, 178 patients with resectable primary tumors were enrolled at 29 centers in

249 ng a better definition of which patients are resectable, randomized studies comparing perioperative w

250 tic disease and whose disease was considered resectable received one of four prospectively randomized

251 oradiotherapy (CT-RT) regimens in T3-4 Nx M0 resectable rectal cancer.

252 in the adjuvant management of patients with resectable rectal cancer.

253 nation, however, failed to identify a single resectable recurrence, and the total cost for physician

254 Recurrence, resectable recurrence, surgical mortality, and survival

255 ancer is recommended principally to identify resectable recurrences, but data on the efficacy of, out

256 with worse survival and aggressive rarely re-resectable recurrences.

257 fter ILI with ability to identify surgically resectable recurrent disease in these high-risk patients

258 on-small-cell lung cancer (NSCLC), even when resectable, remains poor.

259 RT) for patients with localized, potentially resectable retroperitoneal sarcomas (RPS).

260 tandard of care for patients with localized, resectable retroperitoneal sarcomas is surgical resectio

261 rgical response was classified as completely resectable (S-CR), partially resectable (S-PR), or unres

262 d as completely resectable (S-CR), partially resectable (S-PR), or unresectable (S-UR).

263 Eighteen patients with surgically resectable SCUC received neoadjuvant treatment with a me

264 s of neoadjuvant chemotherapy for surgically resectable SCUC.

265 s, for which chemotherapy is used to reach a resectable situation (downsizing).

266 ion for patients with localized, potentially resectable soft tissue sarcomas of the extremities or bo

267 effective in detecting most HCC tumors at a resectable stage and significantly prolonged survival ra

268 Eligibility criteria included resectable stage I to III cancer of the mid-/distal-esop

269 oadjuvant chemoradiotherapy in patients with resectable stage II-III rectal cancer.

270 surgery with definitive chemoradiotherapy in resectable stage III disease after induction.

271 imen and optimal management of patients with resectable stage III disease.

272 PFS rates in randomly assigned patients with resectable stage III non-small-cell lung cancer were exc

273 py followed by CCR for organ preservation in resectable stage III/IVA and IVB larynx and oropharynx (

274 Eligibility required resectable stage T2N+, or T3-T4N0-3M0 biopsy-proven squa

275 tively successful, detecting most PDACs at a resectable stage.

276 and a longer remission duration (P=0.02) in resectable-staged patients.

277 One hundred patients with potentially resectable suspected NSCLC were enrolled.

278 irteen (81%) of 16 patients initially judged resectable, three (33%) of nine borderline-resectable pa

279 giopoietin/Tie2 pathway, in a mouse model of resectable triple-negative breast cancer (TNBC).

280 Of 44 cases with resectable tumor on CT scan, EUS-FNA avoided thoracotomy

281 59 patients were identified with potentially resectable tumors (pretreatment clinical Stage I: T1N0M0

282 vely; the 2-year OS was 59% in patients with resectable tumors and was 25% in patients with unresecta

283 for patients with resectable and borderline-resectable tumors is cure, facilitated by achieving marg

284 with 5-year survival rates for patients with resectable tumors ranging from 15% to 20%.

285 We randomly assigned patients with resectable tumors to receive surgery alone or weekly adm

286 B tumors, 5-year survival rates were 95% for resectable tumors versus 78% for unresectable mesenteric

287 induction, 161 (65.4%) of 246 patients with resectable tumors were randomly assigned; strata were tu

288 urvival (OS), particularly for patients with resectable tumors without extrahepatic disease.

289 atients with rapidly growing or incompletely resectable tumors, so these patients should be managed n

290 sent in 46% of pancreatic cancers and 55% of resectable tumors.

291 of surgical hepatic resection versus RFA for resectable tumors; the utility of RFA for unresectable t

292 soft tissue with locally advanced disease or resectable tumours requiring extensive surgery, an Easte

293 recurrence rates in patients with initially resectable tumours.

294 is the treatment of choice in patients with resectable tumours.

295 ter that therapy, patients whose tumors were resectable underwent surgery and then received two addit

296 injectable melanoma that was not surgically resectable were randomly assigned at a two-to-one ratio

297 initially unresectable CRC liver metastases resectable, while at the same time distinguishing betwee

298 urrent but not resectable, and recurrent but resectable with curative intent.

299 atic colorectal cancer (CRC) can be rendered resectable with systemic chemotherapy in approximately 2

300 period, 22 patients had disease that was not resectable without amputation.